In this issue: Knock on effects of the Valsartan recall, the future of...
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
- Allergan assesses brazikumab in two clinical programmes for IBD
- AstraZeneca reports negative top-line results from TULIP 1 trial
Tisotumab vedotin shows promise in treating six cancer types
A Phase I/II global clinical trial demonstrated that a new drug called tisotumab vedotin (TV), which uses ‘Trojan horse’ approach to enter into tumour cells, can treat six different types of cancer.
January’s top news stories
Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
Women’s health pipeline: profiling the GCPR target class
Health disorders in women can be caused by many abnormalities in the body and represent a very broad therapy area. Drug development for women’s health disorders has lagged behind other therapy areas, and few new therapies have been approved in the past years.
2018: The year’s biggest Drug Development Technology stories
The US National Institutes of Health (NIH) has provided funding for a clinical trial to examine the effectiveness of male contraceptive skin gel NES/T, and GlaxoSmithKline (GSK) has started its Phase III trial evaluating Benlysta (belimumab) in combination with rituximab to treat adult patients with systemic lupus erythematosus (SLE). Drug Development Technology wraps up the key headlines from 2018.
FDA accelerated review denial is a blow to Spectrum’s poziotinib
On December 19, Spectrum Pharmaceuticals’ shares tumbled 31% following the FDA decision to decline the company’s request of a breakthrough therapy designation (BTD) for its clinical candidate EGFR tyrosine kinase inhibitor (TKI) poziotinib for the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC).
Chinese biotech hits new heights with approval of first domestic checkpoint inhibitor
On December 17, China’s National Medical Products Authority (NMPA) conditionally approved the listing of the first locally developed programmed cell death-1 (PD-1) checkpoint inhibitor, Tuoyi (toripalimab) monoclonal antibody injection for the treatment of melanoma.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.